The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AGN-PC-00CGUS     2-[4-[2-[[2-(3-chlorophenyl)- 2-hydroxy...

Synonyms: AG-K-03277, SureCN3692642, ACMC-20djmh, Brl-37344, CHEBI:132852, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Brl 37344A


High impact information on Brl 37344A


Biological context of Brl 37344A


Anatomical context of Brl 37344A

  • DESIGN: Single and whole-cell electrophysiological BK(Ca) channel recordings from freshly dispersed myocytes were obtained in the presence and absence of BRL37344, a specific beta3-adrenoreceptor agonist [9].
  • Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist BRL 37344 had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels [12].
  • BRL37344 (100 micromol/) did not alter current amplitudes of KvLQT1/minK expressed in CHO cells or in Xenopus oocytes, excluding a direct effect of BRL37344 on the channel [10].
  • Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle [13].
  • Background and purpose:In cardiac muscle, BRL 37344, a selective beta(3)-adrenoceptor agonist, activates the Na(+),K(+)-pump via NO signalling [14].

Associations of Brl 37344A with other chemical compounds

  • Similar negative inotropic effects also resulted from the action of beta3-adrenoceptor agonists with an order of potency: BRL 37344 > SR 58611 approximately CL 316243 > CGP 12177 [15].
  • The rank order of potency of agonists in functional and binding studies was BRL37344 greater than IPR less than (-)-norepinephrine greater than (-)-epinephrine both in 3T3 adipocytes and CHO-beta 3 cells [16].
  • Following butyrate treatment, EC50 values of beta 1- and beta 2-selective agonists, dobutamine and fenoterol, were decreased, whereas that of the beta 3-selective agonist BRL37344 was increased [17].
  • In vitro isometric tension studies demonstrated that BRL37344 exerted a significant concentration-dependent relaxant effect on human myometrial tissue (P < 0.05), and preincubation of these strips with IbTX attenuated this effect on both spontaneous and oxytocin-induced contractions (44.44 and 57.84% at 10(-5) M, respectively) [9].
  • In addition, BRL 37344 and propranolol, ligands that act as agonists in the stimulation of cyclase, act as antagonists for ERK activation [18].

Gene context of Brl 37344A

  • The selective beta3-adrenoceptor agonist BRL-37344 failed to affect anti-IgE-induced histamine release from cultured mast cells [19].
  • The ob gene mRNA half-life was 9.4 h and was decreased to 2.4 h by 1 nM BRL 37344, indicating that the inhibitory effect of the beta 3-agonist might be due to destabilization of ob gene mRNA [20].
  • By contrast, BRL 37344 and CGP 12177 increased the expression of UCP2 and UCP3 in both wild type and beta(3)-AR KO mice, whereas they increased the expression of PGC-1 in wild type mice only [21].
  • Atypical beta-AR and beta 3-AR had an affinity about 10-50 times higher for sodium-4-(2-[2-hydroxy-2-(3-chlorophenyl)ethylamino]propyl)phenoxyace tate sesquihydrate (BRL37344) than the beta 1-AR subtype [16].
  • Administration of BRL37344 to mice reduced ApN mRNAs in both adipose regions, and ApN levels in plasma [22].

Analytical, diagnostic and therapeutic context of Brl 37344A


  1. Functional beta-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes. Boivin, B., Lavoie, C., Vaniotis, G., Baragli, A., Villeneuve, L.R., Ethier, N., Trieu, P., Allen, B.G., Hébert, T.E. Cardiovasc. Res. (2006) [Pubmed]
  2. Effect of the adrenergic beta 3-agonist, BRL37344, on heat production by brown adipocytes in obese and in older rats. Yamakawa, A., Tanaka, E., Nakano, S. Tokai J. Exp. Clin. Med. (1994) [Pubmed]
  3. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. Gauthier, C., Leblais, V., Kobzik, L., Trochu, J.N., Khandoudi, N., Bril, A., Balligand, J.L., Le Marec, H. J. Clin. Invest. (1998) [Pubmed]
  4. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Bing, C., Bao, Y., Jenkins, J., Sanders, P., Manieri, M., Cinti, S., Tisdale, M.J., Trayhurn, P. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  5. Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Cirino, G., Sorrentino, R., di Villa Bianca, R., Popolo, A., Palmieri, A., Imbimbo, C., Fusco, F., Longo, N., Tajana, G., Ignarro, L.J., Mirone, V. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  6. Transcriptional down-regulation by insulin of the beta 3-adrenergic receptor expression in 3T3-F442A adipocytes: a mechanism for repressing the cAMP signaling pathway. Fève, B., Elhadri, K., Quignard-Boulangé, A., Pairault, J. Proc. Natl. Acad. Sci. U.S.A. (1994) [Pubmed]
  7. Beta 3-adrenergic receptors regulate retinal endothelial cell migration and proliferation. Steinle, J.J., Booz, G.W., Meininger, C.J., Day, J.N., Granger, H.J. J. Biol. Chem. (2003) [Pubmed]
  8. An adipose tissue-specific beta-adrenergic receptor. Molecular cloning and down-regulation in obesity. Muzzin, P., Revelli, J.P., Kuhne, F., Gocayne, J.D., McCombie, W.R., Venter, J.C., Giacobino, J.P., Fraser, C.M. J. Biol. Chem. (1991) [Pubmed]
  9. Functional coupling of beta3-adrenoceptors and large conductance calcium-activated potassium channels in human uterine myocytes. Doheny, H.C., Lynch, C.M., Smith, T.J., Morrison, J.J. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  10. beta3-Adrenergic regulation of an ion channel in the heart-inhibition of the slow delayed rectifier potassium current I(Ks) in guinea pig ventricular myocytes. Bosch, R.F., Schneck, A.C., Kiehn, J., Zhang, W., Hambrock, A., Eigenberger, B.W., Rüb, N., Gogel, J., Mewis, C., Seipel, L., Kühlkamp, V. Cardiovasc. Res. (2002) [Pubmed]
  11. The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. Tavernier, G., Galitzky, J., Bousquet-Melou, A., Montastruc, J.L., Berlan, M. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  12. Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. Borger, P., Hoekstra, Y., Esselink, M.T., Postma, D.S., Zaagsma, J., Vellenga, E., Kauffman, H.F. Am. J. Respir. Cell Mol. Biol. (1998) [Pubmed]
  13. Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle. Liu, Y.L., Cawthorne, M.A., Stock, M.J. Br. J. Pharmacol. (1996) [Pubmed]
  14. beta(3)-Adrenoceptor agonist stimulation of the Na(+),K(+)-pump in rat skeletal muscle is mediated by beta(2)- rather than beta(3)-adrenoceptors. Murphy, K.T., Bundgaard, H., Clausen, T. Br. J. Pharmacol. (2006) [Pubmed]
  15. Functional beta3-adrenoceptor in the human heart. Gauthier, C., Tavernier, G., Charpentier, F., Langin, D., Le Marec, H. J. Clin. Invest. (1996) [Pubmed]
  16. Atypical beta-adrenergic receptor in 3T3-F442A adipocytes. Pharmacological and molecular relationship with the human beta 3-adrenergic receptor. Fève, B., Emorine, L.J., Lasnier, F., Blin, N., Baude, B., Nahmias, C., Strosberg, A.D., Pairault, J. J. Biol. Chem. (1991) [Pubmed]
  17. Transcriptional modulation by n-butyric acid of beta 1-, beta 2-, and beta 3-adrenergic receptor balance in 3T3-F442A adipocytes. Krief, S., Fève, B., Baude, B., Zilberfarb, V., Strosberg, A.D., Pairault, J., Emorine, L.J. J. Biol. Chem. (1994) [Pubmed]
  18. Stimulation of the extracellular signal-regulated kinase 1/2 pathway by human beta-3 adrenergic receptor: new pharmacological profile and mechanism of activation. Gerhardt, C.C., Gros, J., Strosberg, A.D., Issad, T. Mol. Pharmacol. (1999) [Pubmed]
  19. Beta-adrenoceptor-mediated inhibition of mediator release from human peripheral blood-derived mast cells. Wang, X.S., Lau, H.Y. Clin. Exp. Pharmacol. Physiol. (2006) [Pubmed]
  20. Effects of beta-adrenoceptor subtype stimulation on obese gene messenger ribonucleic acid and on leptin secretion in mouse brown adipocytes differentiated in culture. Deng, C., Moinat, M., Curtis, L., Nadakal, A., Preitner, F., Boss, O., Assimacopoulos-Jeannet, F., Seydoux, J., Giacobino, J.P. Endocrinology (1997) [Pubmed]
  21. Role of the beta(3)-adrenergic receptor and/or a putative beta(4)-adrenergic receptor on the expression of uncoupling proteins and peroxisome proliferator-activated receptor-gamma coactivator-1. Boss, O., Bachman, E., Vidal-Puig, A., Zhang, C.Y., Peroni, O., Lowell, B.B. Biochem. Biophys. Res. Commun. (1999) [Pubmed]
  22. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Delporte, M.L., Funahashi, T., Takahashi, M., Matsuzawa, Y., Brichard, S.M. Biochem. J. (2002) [Pubmed]
  23. Stereoselective action of (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)ethylamino] propyl]-phenoxyacetic acid (BRL37344) on beta-adrenoceptors and metabolic chiral inversion. Ida, K., Hashimoto, K., Kamiya, M., Muto, S., Nakamura, Y., Kato, K., Mizota, M. Biochem. Pharmacol. (1996) [Pubmed]
  24. Beta2- and beta3-adrenoreceptor agonists: human myometrial selectivity and effects on umbilical artery tone. Dennedy, M.C., Houlihan, D.D., McMillan, H., Morrison, J.J. Am. J. Obstet. Gynecol. (2002) [Pubmed]
  25. Comparison of effects of formoterol and BRL 37344 on isolated term-pregnant rat myometrial strips in vitro. Yurtcu, N., Cetin, A., Karadas, B., Gonca Imir, A., Kaya, T., Erselcan, T., Bagcivan, I., Cetin, M. Eur. J. Pharmacol. (2006) [Pubmed]
  26. Pharmacological evidence for beta3 adrenoceptors in the control of rat gastric acid secretion. Adami, M., Coruzzi, G., Sotirov, E., Bertini, S., Soldani, G. Dig. Dis. Sci. (2003) [Pubmed]
WikiGenes - Universities